UNSPSC 51111780: Durvalumab

Durvalumab is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca.[5] It is a human immunoglobulin G1 kappa (IgG1?) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279).

UNSPSC 51111780 Durvalumab, a Commodity code, has no identifiable recent state and local procurement activity. The source contains sixteen recent opportunity records across state and local jurisdictions, none of which solicits durvalumab or any pharmaceutical product matching this code's specific scope. The opportunities posted between January and July 2026 span medical oxygen and cylinder rental (Little Rock Fire Department, ITQ 219399); naloxone and drug deactivation systems (Seminole County, Florida, IFB); basic and advanced life support pharmaceuticals and supplies (Tucson Fire Department, RFP); generic multi-source pharmaceuticals through cooperative purchasing (Minnesota MMCAP, RFP); forensic drug standards for laboratory analysis (Pinellas County, Florida, ITQ); and clinic and wellness services (Collier County, Florida, RFP). The remaining records document vendor networking events, informational forums, trade shows, and departmental relocation notices rather than product procurement. None of these opportunities explicitly names durvalumab, an immunotherapy oncology agent, or solicits pharmaceutical manufacturing, distribution, or clinical supply arrangements aligned with the code's nominal scope.

The code shows no discernible recent buy-side activity among state and local governments. Without identifiable solicitations, issuing-body patterns, or geographic concentration, the code does not support a pursue decision at this time. Vendors should monitor state health department, Medicaid managed care, and regional cancer center procurement channels directly rather than relying on UNSPSC 51111780 as a discovery mechanism for durvalumab opportunities in the state and local market.